estrogens conjugated, Premarin (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

The Women's Health Initiative found that postmenopausal women (50-79 years old) taking conjugated estrogens, 0.625 mg daily, in combination with medroxyprogesterone, 2.5 mg daily, for five years, had an increased risk of heart attacks, stroke, breast cancer, and blood clots, while postmenopausal women taking conjugated estrogens without progesterone experienced only increased strokes but not increased blood clots, heart disease, or breast cancer.

There was an increased risk of impaired cognition and/or dementia among women over age 65 treated with either estrogens or estrogens and medroxyprogesterone.



PREPARATIONS: Tablets: 0.3, 0.45, 0.625, 0.9, and 1.25 mg. Vaginal cream: 0.625 mg per gm of cream. Injection: 25 mg per vial

STORAGE: Conjugated estrogen tablets and cream should be stored at room temperature, between 15 C -30 C (59 F - 86 F). The injection should be stored between 2 C - 8 C (36 F - 46 F).

DOSING: To minimize side effects, the lowest effective oral dose of conjugated estrogens is used. The usual starting dose for treating symptoms associated with menopause and for preventing postmenopausal osteoporosis is 0.3 mg/day. The dose should be increased based on response.

Conjugated estrogens may be administered continuously or in a cyclical fashion (i.e., 25 days on treatment then 5 days off treatment).

Hypogonadism is treated cyclically with doses of 0.3 mg or 0.625 mg daily for 25 days followed by 5 days off treatment.

Medically Reviewed by a Doctor on 1/29/2015

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index